Broadening cancer patient access to powerful disease-transforming immunotherapy
Our therapeutic approach transiently blocks DNA Mismatch Repair (MMR) to mimic the known robust and durable clinical responses to immunotherapy of patients with genetically MMR-deficient tumours.
Our Vision
Our medicine will bring the proven therapeutic benefits of cancer immunotherapy to substantially more cancer patients.
Clinicians commonly observe robust and durable immune responses against certain cancers that lack components of DNA mismatch repair (MMR); so-called MMR-deficient (MMR-d) tumours. However, most patient tumours are MMR proficient (MMR-p) and unresponsive to immunotherapy. We aim to transform MMR-p tumours to an MMR-d state by transiently blocking MMR with a small molecule therapeutic, thereby rendering those tumours sensitive to immunotherapy.
Our Hypothesis
Short-term pharmacological inhibition of MMR, either alone or in combination with standard-of-care treatments, will reprogramme hitherto unresponsive MMR-p tumours to an immune-responsive state (MMR-d) with the potential to expand cancer patient access to durable immunotherapy responses.